Literature DB >> 3744858

Methylphenidate treatment of patients with head and neck cancer.

F Fernandez, F Adams.   

Abstract

Five organically impaired and depressed head and neck cancer patients had a marked therapeutic response to methylphenidate (MPD). There was a rapid remission of depressive and cognitive dysfunctions without adverse side effects. The relationship of cognitive, behavioral, and affective symptoms to brain function is discussed. To rule out treatable cognitive and affective disorders, neurobehavioral assessment of the depressed head and neck cancer patient is stressed, and diagnostic and treatment guidelines are given. The results suggest that further evaluation is warranted of the use of MPD in treating seriously ill cancer patients who have either compromised brain function or depression.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3744858     DOI: 10.1002/hed.2890080410

Source DB:  PubMed          Journal:  Head Neck Surg        ISSN: 0148-6403


  4 in total

1.  Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study.

Authors:  Bruno Gagnon; Graeme Low; Gil Schreier
Journal:  J Psychiatry Neurosci       Date:  2005-03       Impact factor: 6.186

2.  A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor.

Authors:  K Gehring; S Y Patwardhan; R Collins; M D Groves; C J Etzel; C A Meyers; J S Wefel
Journal:  J Neurooncol       Date:  2011-10-02       Impact factor: 4.130

3.  Decreased serum glucose levels after initiation of methylphenidate in a patient status post-cerebellar tumour resection: a potential interaction with glipizide.

Authors:  Samuel T Gontkovsky; Robert Nevels; Nicholas B McDonald; Michael H Winkelmann
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

4.  Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate.

Authors:  T J Volz
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.